# Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease

> **NCT02054208** · PHASE1,PHASE2 · COMPLETED · sponsor: **Medipost Co Ltd.** · enrollment: 46 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **BIOLOGICAL:** human umbilical cord blood derived mesenchymal stem cells
- **OTHER:** Normal saline 2mL

## Key facts

- **NCT ID:** NCT02054208
- **Lead sponsor:** Medipost Co Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2020-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02054208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02054208, "Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02054208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*